Antifungal Resistance is a Public Health Challenge
"Candida is a leading cause of healthcare-associated bloodstream infections in U.S. hospitals. Each case of Candida bloodstream infection is estimated to result in an additional 3 to 13 days of hospitalization and $6,000 to $29,000 in healthcare costs. About 7% of all Candida bloodstream isolates tested at CDC are resistant to fluconazole and more than 70% of these resistant isolates are Candida glabrata or Candida krusei."1
In two studies of patients with Candida bloodstream infections, delays of 12-14 hours resulted in a mortality rate 2-3 times higher compared to patients who received more timely antifungal therapy.2,3
The IDSA Recommends Antifungal Susceptibility Testing for Bloodstream Infections4.
The VITEK 2 AST-YS09 panel includes: caspofungin, fluconazole, flucytosine, micafungin, and voriconazole. This card provides an automated and standardized antifungal susceptibility testing platform.
AST-YS09 card (Ref. 423331) calling ranges:
| Antifungal Agents |
Calling Range |
| ≤ |
≥ |
| Caspofungin |
0.125 |
8 |
| Fluconazole |
0.5 |
64 |
| Flucytosine |
1 |
64 |
| Micafungin |
0.06 |
8 |
| Voriconazole |
0.12 |
8 |
Additional antifungal agents are available with ETEST®—a reliable and valuable manual MIC AST solution to guide therapy and manage treatment.
For more information, please fill out the Request More Information Form and a bioMérieux, Inc. representative will contact you.
REFERENCES
1. Antifungal Resistance. Centers for Disease Control website https://www.cdc.gov/fungal/antifungal-resistance.html Updated September 6, 2018. Accessed April 29, 2019.
2. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Inf Control Hosp Epidemiol. 2005;26:540-547. DOI: 10.1086/502581
3. Vallabhaneni S, Cleveland A, Farley M, et al. Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstreamiInfections: Data from a large multisite population-based candidemia surveillance program, 2008–2014. Open Forum Infect Dis. 2015;2(4):ofv163. DOI: 10.1093/ofid/ofv163
4. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50. DOI: 10.1093/cid/civ933
